IMMIX BIOPHARMA, INC. Accounts Payable
IMMIX BIOPHARMA, INC. (IMMX) had Accounts Payable of $5.28 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-07
- 2026-06-30: Accounts Payable, Current $5.28M.
- 2026-03-31: Accounts Payable, Current $4.73M.
- 2025-12-31: Accounts Payable, Current $5.44M.
- 2025-09-30: Accounts Payable, Current $7.05M.
| Period end | Accounts Payable, Current |
|---|---|
| 2026-06-30 | $5.28M 10-Q · filed 2026-08-07 |
| 2026-03-31 | $4.73M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $5.44M 10-Q · filed 2026-08-07 |
| 2025-09-30 | $7.05M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $6.61M 10-Q · filed 2025-08-08 |
| 2025-03-31 | $5.74M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $5.39M 10-K/A · filed 2026-03-27 |
| 2024-09-30 | $3.29M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $2.35M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $3.51M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $1.43M 10-K · filed 2025-03-25 |
| 2023-09-30 | $1.57M 10-Q · filed 2023-11-13 |
| 2022-12-31 | $143.07K 10-K · filed 2024-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |